LATE-BREAKING ABSTRACT: Epidemiology of IPF in Italy

S. Harari, F. Madotto, A. Caminati, S. Conti, G. Cesana (Via San Vittore 12, Milano, Via Bicocca degli Arcimboldi 8, Milano, Italy)

Source: International Congress 2014 – ILDs 6
Session: ILDs 6
Session type: Thematic Poster Session
Number: 3781
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Abstract

IntroductionDespite its clinical relevance, IPF remains an uncommon disorder and few studies have focused on its epidemiology. Aim of the study is to investigate the prevalence and incidence of IPF in Lombardy, an Italian region with universal healthcare coverage for almost 10 million people, during 2005-2010.MethodsSubjects affected by IPF were identified using healthcare administrative databases of Lombardy Health System: vital status, hospitalizations and outpatient visits. We estimated annual standardized prevalence and incidence rates (100,000 person-years) adopting three different algorithms to identify IPF cases, called generic, broad and narrow case definition (GCD, BCD, NCD).ResultsThe mean annual prevalence rate was 35.5, 22.4 and 12.6 using respectively GCD, BCD and NCD. Prevalence increased with age and BCD and NCD showed a significantly higher rate in men. During the study period, we detected a positive trend of the annual prevalence rate. Annual incidence was estimated to 5.3 with GCD, 3.7 with BCD and 2.3 with NCD; like prevalence, incidence was higher among man than women and in elderly. Adopting GCD, we observed a decreasing trend in annual incidence rate (from 6.1 in 2005 to 4.5 in 2010), while the other case definitions detected a stable trend in annual incidence.ConclusionsIn Lombardy, IPF prevalence increased while incidence remained stable in the last years. It is therefore likely that disease duration has lengthened. The IPF prevalence and incidence identified in our population are lower than those reported by American studies and are consistent with those observed in other European studies.


Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Harari, F. Madotto, A. Caminati, S. Conti, G. Cesana (Via San Vittore 12, Milano, Via Bicocca degli Arcimboldi 8, Milano, Italy). LATE-BREAKING ABSTRACT: Epidemiology of IPF in Italy. Eur Respir J 2014; 44: Suppl. 58, 3781

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study
Source: International Congress 2014 – IPF and surroundings
Year: 2014


Epidemiology of Idiopathic Pulmonary Fibrosis in Australia
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021


LATE-BREAKING ABSTRACT: Current management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014


LATE-BREAKING ABSTRACT: The effects and mechanism of adiponectin on inhibiting pulmonary fibrosis
Source: International Congress 2014 – ILDs 1
Year: 2014


Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort
Source: International Congress 2014 – ILDs 4
Year: 2014


Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis
Source: International Congress 2014 – ILDs 5
Year: 2014


Desquamative interstitial pneumonia in a Danish cohort, treatment response and outcome
Source: International Congress 2014 – ILDs 2
Year: 2014

Pregnancy course in patients with interstitial lung diseases
Source: International Congress 2014 – ILDs 5
Year: 2014


Evolution of an interstitial lung disease MDT: 5.5 years of data
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014


Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014


Reduction in disease progression with nintedanib in the INPULSIS™ trials
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014


Clinical features of four children with pulmonary alveolar proteinosis
Source: International Congress 2014 – ILDs 5
Year: 2014


Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014



LATE-BREAKING ABSTRACT: Bosentan in Pulmonary Hypertension associated with Fibrotic Idiopathic Interstitial Pneumonia:A Randomized, Double-Blind, Placebo-controlled Study
Source: Annual Congress 2013 –Pulmonary circulation: treatment
Year: 2013


Management of spontaneous pneumothorax in patients with or without Birt-Hogg-Dubé syndrome
Source: International Congress 2014 – ILDs 1
Year: 2014

Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 2
Year: 2014

The effect of pirfenidone with patients with idiopathic pulmonary fibrosis in one university hospital
Source: International Congress 2014 – ILDs 4
Year: 2014


IPFdatabase – A new tool for a correct application of idiopathic pulmonary fibrosis guidelines
Source: International Congress 2014 – ILDs 2
Year: 2014

Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 3
Year: 2014


Combined pulmonary fibrosis and emphysema: A report from the Hellenic Interstitial Lung Diseases group
Source: Annual Congress 2010 - Different patterns of interstitial lung disease
Year: 2010